UK regulators seize illegal weight loss drugs amid global pricing shake-up
UK drug regulators have shut down an illicit manufacturing facility producing counterfeit glucagon-like peptide-1 receptor agonist (GLP1-RA) medications in the …
Post
-
-
Dupixent stirs Sanofi’s growth as vaccine sales cool
A 26.2% increase in sales for anti-inflammatory blockbuster Dupixent (dupilumab) ensured Sanofi had a strong Q3, despite the company’s vaccine …
-
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In …
-
Galderma outlays $650m for US manufacturing as Nemluvio sales soar
Galderma has pledged to invest more than $650m on US manufacturing, as the drugmaker looks to meet increasing demand for …
-
EUROAPI’s Med4Cure project to strengthen pharma sovereignty
EUROAPI has announced Med4Cure, an initiative within the Health Important Project of Common European Interest (IPCEI) framework, to strengthen pharmaceutical …
-
GSK’s Blenrep gains FDA approval for myeloma treatment
GSK has received US Food and Drug Administration (FDA) approval for Blenrep (belantamab mafodotin-blmf) to be used along with bortezomib …
-
Demystifying the immune system with the help of AI-ML
Immunotherapy drugs continue to gain momentum across a growing range of disease areas with blockbusters such as MSD's Keytruda (pembrolizumab) …
-
Roche in ongoing discussions with US government over drug pricing, CEO says
Roche’s CEO Thomas Schinecker said the drugmaker is continuing talks with the US government over drug pricing reforms, as President …
-
Biotech recovery in Q3 2025 as venture funding grows 70.9% from Q2 2025
GlobalData’s Venture Capital Investment Trends In Pharma – Q3 2025 report revealed that the biotech industry witnessed a 70.9% increase …
-
Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls
Takeda and Innovent Biologics have signed a deal worth up to $11.4bn following its bid to focus on bispecifics and …
-
Remote monitoring: The tech enhancing diabetes management in Scotland
With diabetes diagnoses growing globally, remote monitoring technologies developed in Scotland are now providing essential solutions for managing the condition. The …
-
Ipsen to buy French biotech company ImCheck Therapeutics
Ipsen is set to purchase all issued and outstanding shares of the French biotechnology company ImCheck Therapeutics, which specialises in …
-
Biotechs brush off sector headwinds in venture financing rebound
Early-stage equity raises for biotechs surged by 71% in Q3 2025, suggesting the funding freeze that has gripped the industry …
-
Alkermes to acquire Avadel for $2.1bn
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The acquisition …
-
The future of high-potency APIs: Strategies for manufacturing challenges
The growing friction between the US and China has serious consequences for the supplies of high-potency active pharmaceutical ingredients (HPAPIs), …
